Nektar Therapeutics
NKTR
Delayed Nasdaq - 07/18 10:00:00 pm
47.88USD
-0.99%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales3081 179
EBITDA-28,9645
Operating profit (EBIT)-43,7669
Pre-Tax Profit (EBT)--
Net income-96,7620
EPS ( $ )-0,623,73
Dividend per Share ( $ )--
Yield--
Announcement Date03/01/2018
09:40pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt--
Finance50,9-
Operating income (EBITDA)-28,9645
Leverage
(Debt/EBITDA)
--
Capital Expenditure9,685,25
Book Value Per Share (BVPS)0,55 $9,84 $
Cash Flow per Share-0,52 $3,93 $
Announcement Date03/01/2018
09:40pm
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 8 289 M$ -
Entreprise Value (EV) - 8 289 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 13,0x
Capitalization / Revenue 7,03x 30,0x
EV / Revenue - -
EV / EBITDA - -
Yield (DPS / Price) - -
Price to book (Price / BVPS) 4,91x 43,5x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 56,7% -83,6%
operating Leverage (Delta EBIT / Delta Sales) 5,77x -1,76x
Net Margin (Net Profit / Revenue) 52,6% -94,0%
ROA (Net Profit / Asset) 36,0% 7,00%
ROE (Net Profit / Equities) 36,0% 8,00%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   0,45% 3,66%
Cash Flow / Sales 57,1% -
Capital Intensity (Assets / Sales) 1,46x -13,4x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
BNA & Dividende